Mikhael F El-Chami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9564706/publications.pdf

Version: 2024-02-01

122 papers

4,365 citations

31 h-index

147801

62 g-index

122 all docs 122 docs citations

122 times ranked

4383 citing authors

#	Article	IF	Citations
1	Predictors and Clinical Outcomes of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, 60-69.	2.9	441
2	New-Onset Atrial Fibrillation Predicts Long-Term Mortality After Coronary Artery Bypass Graft. Journal of the American College of Cardiology, 2010, 55, 1370-1376.	2.8	299
3	Subcutaneous or Transvenous Defibrillator Therapy. New England Journal of Medicine, 2020, 383, 526-536.	27.0	278
4	A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm, 2017, 14, 1375-1379.	0.7	251
5	Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Heart Rhythm, 2018, 15, 1800-1807.	0.7	239
6	Long-term performance of a transcatheter pacing system: 12-Month results from the Micra Transcatheter Pacing Study. Heart Rhythm, 2017, 14, 702-709.	0.7	230
7	Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes. Journal of the American College of Cardiology, 2015, 66, 1378-1391.	2.8	164
8	Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm, 2017, 14, 1456-1463.	0.7	137
9	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation, 2021, 143, 7-17.	1.6	132
10	Leadless pacemaker implant in patients with preâ€existing infections: Results from the Micra postapproval registry. Journal of Cardiovascular Electrophysiology, 2019, 30, 569-574.	1.7	97
11	Blunt Cardiac Trauma. Journal of Emergency Medicine, 2008, 35, 127-133.	0.7	80
12	Leadless pacemakers reduce risk of device-related infection: Review of the potential mechanisms. Heart Rhythm, 2020, 17, 1393-1397.	0.7	78
13	The Subcutaneous Defibrillator. Journal of the American College of Cardiology, 2014, 63, 1473-1479.	2.8	74
14	Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up. European Heart Journal, 2022, 43, 1207-1215.	2.2	72
15	Long-term outcomes in leadless Micra transcatheter pacemakers with elevated thresholds at implantation: Results from the Micra Transcatheter Pacing System Global Clinical Trial. Heart Rhythm, 2017, 14, 685-691.	0.7	63
16	Development of a Risk Score to Predict New Pacemaker Implantation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 2133-2142.	2.9	60
17	Contemporaneous Comparison of Outcomes Among Patients Implanted With a Leadless vs Transvenous Single-Chamber Ventricular Pacemaker. JAMA Cardiology, 2021, 6, 1187.	6.1	57
18	Incidence and outcomes of systemic infections in patients with leadless pacemakers: Data from the Micra IDE study. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1105-1110.	1.2	56

#	Article	IF	CITATIONS
19	Leadless Pacemaker Implantation inÂHemodialysis Patients. JACC: Clinical Electrophysiology, 2019, 5, 162-170.	3.2	54
20	Outcome of Subcutaneous Implantable Cardioverter Defibrillator Implantation in Patients with Endâ€6tage Renal Disease on Dialysis. Journal of Cardiovascular Electrophysiology, 2015, 26, 900-904.	1.7	53
21	How to Implant a Leadless Pacemaker With a Tineâ€Based Fixation. Journal of Cardiovascular Electrophysiology, 2016, 27, 1495-1501.	1.7	50
22	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm, 2019, 16, 1636-1644.	0.7	48
23	Impact of race and gender on cardiac device implantations. Heart Rhythm, 2007, 4, 1420-1426.	0.7	47
24	Performance of a novel left ventricular lead with short bipolar spacing for cardiac resynchronization therapy: Primary results of the Attain Performa Quadripolar Left Ventricular Lead Study. Heart Rhythm, 2015, 12, 751-758.	0.7	44
25	Prediction of New Onset Atrial Fibrillation After Cardiac Revascularization Surgery. American Journal of Cardiology, 2012, 110, 649-654.	1.6	43
26	Magnetic resonance imaging safety in nonconditional pacemaker and defibrillator recipients: A meta-analysis and systematic review. Heart Rhythm, 2018, 15, 1001-1008.	0.7	42
27	Clinical outcomes three years after PLAATO implantation. Catheterization and Cardiovascular Interventions, 2007, 69, 704-707.	1.7	41
28	Management of Newâ€Onset Postoperative Atrial Fibrillation Utilizing Insertable Cardiac Monitor Technology to Observe Recurrence of AF (MONITORâ€AF). PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1083-1089.	1,2	41
29	Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing. American Heart Journal, 2019, 214, 167-174.	2.7	41
30	Implantable Cardioverter-Defibrillators at End of Battery Life. Journal of the American College of Cardiology, 2016, 67, 435-444.	2.8	40
31	Pacing Features That Mimic Malfunction: A Review of Current Programmable and Automated Device Functions That Cause Confusion in the Clinical Setting. Journal of Cardiovascular Electrophysiology, 2009, 20, 453-460.	1.7	39
32	QRS Duration Is Associated With Atrial Fibrillation in Patients With Left Ventricular Dysfunction. Clinical Cardiology, 2010, 33, 132-138.	1.8	32
33	Ventricular Arrhythmia After Cardiac Surgery. Journal of the American College of Cardiology, 2012, 60, 2664-2671.	2.8	31
34	Transthoracic Dobutamine Stress Echocardiography in Patients Undergoing Bariatric Surgery. Obesity Surgery, 2007, 17, 1475-1481.	2.1	30
35	Outcomes of Sprint Fidelis and Riata lead extraction: Data from 2 high-volume centers. Heart Rhythm, 2015, 12, 1216-1220.	0.7	28
36	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. Circulation, 2022, 145, 321-329.	1.6	28

#	Article	IF	CITATIONS
37	Safety and Quality of 1.5-T MRI in Patients With Conventional and MRI-Conditional Cardiac Implantable Electronic Devices After Implementation of a Standardized Protocol. American Journal of Roentgenology, 2016, 207, 599-604.	2.2	27
38	Generator exchange is associated with an increased rate of Sprint Fidelis lead failure. Heart Rhythm, 2012, 9, 1615-1618.	0.7	26
39	Impact of operator experience and training strategy on procedural outcomes with leadless pacing: Insights from the Micra Transcatheter Pacing Study. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 834-842.	1.2	26
40	Leadless pacemakers: a contemporary review. Journal of Geriatric Cardiology, 2018, 15, 249-253.	0.2	26
41	Predictors of Long-Term Survival Following Transvenous Extraction of Defibrillator Leads. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1297-1303.	1.2	25
42	Development and validation of a risk score for predicting pericardial effusion in patients undergoing leadless pacemaker implantation: experience with the Micra transcatheter pacemaker. Europace, 2022, 24, 1119-1126.	1.7	25
43	Extraction of a 4-year-old leadless pacemaker with a tine-based fixation. HeartRhythm Case Reports, 2019, 5, 424-425.	0.4	24
44	1-Year Prospective Evaluation of Clinical Outcomes and Shocks. JACC: Clinical Electrophysiology, 2020, 6, 1537-1550.	3.2	24
45	Long-term performance of a pacing lead family: A single-center experience. Heart Rhythm, 2019, 16, 572-578.	0.7	23
46	Leadless Pacemakers. American Journal of Cardiology, 2017, 119, 145-148.	1.6	22
47	Azithromycin and Risk of Cardiovascular Death. American Journal of Therapeutics, 2015, 22, e122-e129.	0.9	21
48	Reduced bacterial adhesion with parylene coating: Potential implications for Micra transcatheter pacemakers. Journal of Cardiovascular Electrophysiology, 2020, 31, 712-717.	1.7	20
49	Prevalence, predictors, and outcomes of advance directives in implantable cardioverter-defibrillator recipients. Heart Rhythm, 2017, 14, 830-836.	0.7	19
50	Procedural outcomes and long-term survival associated with lead extraction in patients with abandoned leads. Heart Rhythm, 2018, 15, 855-859.	0.7	18
51	Atrioâ€ventricular synchronous pacing with a single chamber leadless pacemaker: Programming and trouble shooting for common clinical scenarios. Journal of Cardiovascular Electrophysiology, 2021, 32, 533-539.	1.7	18
52	Leadless pacemaker implantation and concurrent atrioventricular junction ablation in patients with atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 504-510.	1.2	17
53	Relationship between device-detected burden and duration of atrial fibrillation and risk of ischemic stroke. Heart Rhythm, 2021, 18, 338-346.	0.7	17
54	Clinical Performance of Magnetic Resonance Imaging Conditional and Nonconditional Cardiac Implantable Electronic Devices. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 467-475.	1.2	16

#	Article	IF	CITATIONS
55	Outcomes of lead extraction in young adults. Heart Rhythm, 2017, 14, 537-540.	0.7	16
56	Morbidity and mortality in patients precluded for transvenous pacemaker implantation: Experience with a leadless pacemaker. Heart Rhythm, 2020, 17, 2056-2063.	0.7	16
57	Generator replacement is associated with an increased rate of ICD lead alerts. Heart Rhythm, 2014, 11, 1785-1789.	0.7	15
58	Patient selection, pacing indications, and subsequent outcomes with de novo leadless single-chamber VVI pacing. Europace, 2019, 21, 1686-1693.	1.7	15
59	The Safety and Feasibility of Same-Day Discharge After Implantation of MICRA Transcatheter Leadless Pacemaker System. Journal of Atrial Fibrillation, 2019, 12, 2153.	0.5	15
60	Predictors and outcomes of lead extraction requiring a bailout femoral approach: Data from 2 high-volume centers. Heart Rhythm, 2017, 14, 548-552.	0.7	14
61	Effect of defibrillation threshold testing on effectiveness of the subcutaneous implantable cardioverter defibrillator. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 996-1000.	1.2	13
62	Outcomes of convergent atrial fibrillation ablation with continuous rhythm monitoring. Journal of Cardiovascular Electrophysiology, 2020, 31, 1270-1276.	1.7	13
63	Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions. JAMA Cardiology, 2016, 1, 181.	6.1	12
64	Clinical and electrocardiographic predictors of T wave oversensing in patients with subcutaneous ICD. Journal of Arrhythmia, 2016, 32, 181-185.	1.2	12
65	Transcatheter/leadless pacing. Heart Rhythm, 2018, 15, 624-628.	0.7	12
66	Incidence of Cancer Treatment–Induced Arrhythmia Associated With Novel Targeted Chemotherapeutic Agents. Journal of the American Heart Association, 2018, 7, e010101.	3.7	12
67	Outcomes of Micra leadless pacemaker implantation with uninterrupted anticoagulation. Journal of Cardiovascular Electrophysiology, 2019, 30, 1313-1318.	1.7	12
68	Sexâ€based differences in procedural complications associated with atrial fibrillation catheter ablation: A systematic review and metaâ€analysis. Journal of Cardiovascular Electrophysiology, 2020, 31, 3176-3186.	1.7	12
69	Life cycle management of Micra transcatheter pacing system: Data from a highâ€volume center. Journal of Cardiovascular Electrophysiology, 2021, 32, 484-490.	1.7	12
70	A Predictive Model for the Long-Term Electrical Performance of a Leadless Transcatheter Pacemaker. JACC: Clinical Electrophysiology, 2021, 7, 502-512.	3.2	12
71	Effect of Lipid Levels and Lipid-Lowering Therapy on Restenosis after Coronary Artery Stenting. American Journal of the Medical Sciences, 2006, 331, 270-273.	1.1	11
72	Management of Atrial Fibrillation in Elderly Adults. Journal of the American Geriatrics Society, 2017, 65, 185-193.	2.6	11

#	Article	IF	CITATIONS
73	Intermittent Variation in Paced QRS Morphology: What Is the Mechanism?. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 1267-1269.	1.2	10
74	Pulmonary vein anatomy assessed by cardiac magnetic resonance imaging in patients undergoing initial atrial fibrillation ablation: implications for novel ablation technologies. Journal of Interventional Cardiac Electrophysiology, 2016, 46, 89-96.	1.3	10
75	Longâ€term survival of implantable cardioverter defibrillator recipients with endâ€stage renal disease. Journal of Arrhythmia, 2017, 33, 459-462.	1.2	10
76	Device-related infection in de novo transvenous implantable cardioverter-defibrillator Medicare patients. Heart Rhythm, 2021, 18, 1301-1309.	0.7	10
77	Esophageal Dissection Complicating Transesophageal Echocardiogram—The Lesson to Be Learned: Do Not Force the Issue. Journal of the American Society of Echocardiography, 2006, 19, 579.e5-579.e7.	2.8	9
78	Outcomes of percutaneous vacuumâ€assisted debulking of large vegetations as an adjunct to lead extraction. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1032-1037.	1.2	9
79	Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm, 2020, 17, 1566-1574.	0.7	9
80	Leadless pacemakers: A review of current data and future directions. Progress in Cardiovascular Diseases, 2021, 66, 61-69.	3.1	9
81	Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors. Journal of Atrial Fibrillation, 2021, 13, 2461.	0.5	9
82	Procedural outcomes and longâ€term survival following lead extraction in octogenarians. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 868-872.	1.2	8
83	Diagnosis and management of subcutaneous implantable cardioverterâ€defibrillator infections based on process mapping. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 958-965.	1.2	8
84	Intermediate-term mortality and incidence of ICD therapy in octogenarians after cardiac resynchronization therapy. Journal of Geriatric Cardiology, 2014, 11, 180-4.	0.2	8
85	Outcomes of two versus three incision techniques: Results from the subcutaneous ICD postâ€approval study. Journal of Cardiovascular Electrophysiology, 2021, 32, 792-801.	1.7	7
86	Procedural outcomes and long-term survival following trans-venous defibrillator lead extraction in patients with end-stage renal disease. Europace, 2017, 19, 1994-2000.	1.7	6
87	<p>Using Medicare Claims to Identify Acute Clinical Events Following Implantation of Leadless Pacemakers</p> . Journal of Pragmatic and Observational Research, 2020, Volume 11, 19-26.	1.5	6
88	Cardiac implantable electronic devices in patients with persistent left superior vena cavaâ€"A single center experience. Journal of Cardiovascular Electrophysiology, 2020, 31, 1175-1181.	1.7	6
89	Effect of Surgical Atrial Fibrillation Ablation at the Time of Cardiac Surgery on Risk of Postoperative Pacemaker Implantation. American Journal of Cardiology, 2015, 116, 88-91.	1.6	5
90	Leadless Pacemaker Implant, Anticoagulation Status, and Outcomes: Results From The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm, 2021, , .	0.7	5

#	Article	IF	Citations
91	The subcutaneous implantable cardioverter defibrillator-review of the recent data. Journal of Geriatric Cardiology, 2018, 15, 222-228.	0.2	5
92	Atrial Septal Abnormalities and Cryptogenic Stroke: A Paradoxical Science. The American Heart Hospital Journal, 2005, 3, 99-104.	0.2	4
93	Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival. Texas Heart Institute Journal, 2018, 45, 221-225.	0.3	4
94	Application of contrast echocardiography in the evaluation of a right-sided vegetative lesion. European Journal of Echocardiography, 2007, 8, 501-503.	2.3	3
95	A Diagnostic Response of a Supraventricular Tachycardia to a Ventricular Premature Beat. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 660-662.	1.2	3
96	Subcutaneous implantable cardioverter-defibrillator implantation in a patient with bilateral pectoral deep brain stimulators. HeartRhythm Case Reports, 2018, 4, 109-112.	0.4	3
97	Femoral extraction of transvenous leads and leadless pacemakersâ€"A review of the data, tools, and procedural steps. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1248-1252.	1.2	3
98	Leadless pacemaker implant with concomitant atrioventricular node ablation: Experience with the Micra transcatheter pacemaker. Journal of Cardiovascular Electrophysiology, 2021, 32, 832-841.	1.7	3
99	Clinical and anatomic predictors of need for repeat atrial fibrillation ablation. World Journal of Cardiology, 2017, 9, 742-748.	1.5	3
100	The Use of Echocardiography for the Evaluation of Dyssynchrony. American Journal of the Medical Sciences, 2006, 331, 315-319.	1.1	2
101	Sealing the Left Atrial Appendage: Ready for Prime Time?. American Journal of the Medical Sciences, 2007, 333, 285-289.	1.1	2
102	Pulse Generator Exchange Does Not Accelerate the Rate of Electrical Failure in a Recalled Small Caliber ICD Lead. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1434-1438.	1.2	2
103	Ablation of manifest septal accessory pathways: a single-center experience. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 349-355.	1.3	2
104	Deviceâ€related infection associated with increased mortality risk in de novo transvenous implantable cardioverterâ€defibrillator medicare patients. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	2
105	Process Mapping Strategies to Prevent Subcutaneous Implantable Cardioverterâ€Defibrillator Infections. Journal of Cardiovascular Electrophysiology, 0, , .	1.7	2
106	Atrioventricular Nodal Reentrant Tachycardia Ablation in the Setting of Bilateral Femoral Vein Occlusion. PACE - Pacing and Clinical Electrophysiology, 2013, 36, e97-9.	1.2	1
107	Comparison of echocardiographic and fluoroscopic sizing of the left atrial appendage prior to percutaneous closure. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 157-161.	1.3	1
108	Response to the letter to the editor: Wettability and roughness: Important determinants of bacterial adhesion and biofilm formation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1886-1887.	1.7	1

7

#	Article	IF	CITATIONS
109	The saga of tendril leads continues: Should we continue to bury our heads in the sand?. Journal of Cardiovascular Electrophysiology, 2021, 32, 1122-1123.	1.7	1
110	B-POO4-064 A PROSPECTIVE EVALUATION OF SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR INFECTIONS WITH MID TERM FOLLOW-UP. Heart Rhythm, 2021, 18, S304-S305.	0.7	1
111	Dilated Coronary Sinus With a Persistent Left Superior Vena Cava: Echo and Cath Findings. Journal of Echocardiography, 2005, 3, 156-157.	0.8	1
112	An Aortic Root Abscess Treated Medically: Echocardiographic Follow up. Journal of Echocardiography, 2006, 4, 67-68.	0.8	1
113	Pulmonary Vein Remodeling Following Atrial Fibrillation Ablation: Implications For The Radiographic Diagnosis Of Pulmonary Vein Stenosis. Journal of Atrial Fibrillation, 2016, 9, 1453.	0.5	1
114	Temporal trends of device-related infection in de novo transvenous implantable cardioverter-defibrillator Medicare patients with underlying kidney disease. Heart Rhythm, 2022, 19, 1689-1695.	0.7	1
115	Pseudo-Ventricular Over and Under-Sensing during an Episode of Double Tachycardia. What is the Mechanism?. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 343-345.	1.2	0
116	Letter to the Editor. Clinical Cardiology, 2011, 34, E13.	1.8	0
117	Response to the Letter to the Editor "Selection of Appropriate Patients for Figureâ€ofâ€Eight Suturing During Removal of Large Bore Transfemoral Sheaths†Journal of Cardiovascular Electrophysiology, 2019, 30, 2182-2182.	1.7	0
118	Reply to letter to the editor: "Overcoming difficulties with persistent left superior vena cava― Journal of Cardiovascular Electrophysiology, 2020, 31, 2266-2266.	1.7	0
119	Cardiac implantable device recalls: consequences, and management. HeartRhythm Case Reports, 2021, 7, 795-796.	0.4	0
120	Prospective evaluation of health status, quality of life and clinical outcomes following implantable defibrillator generator exchange. Journal of Geriatric Cardiology, 2021, 18, 720-727.	0.2	0
121	Leadless Pacing—Uncertainties Remain About Safety and Efficacy—Reply. JAMA Cardiology, 2022, , .	6.1	0
122	Diagnostic Pacing Maneuvers for Supraventricular Tachycardia Discrimination: a Taxonomic Approach. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 13-26.	0.9	0